2024
Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities
Valdez C, Sánchez-Zuno G, Bucala R, Tran T. Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities. International Journal Of Molecular Sciences 2024, 25: 4849. PMID: 38732068, PMCID: PMC11084905, DOI: 10.3390/ijms25094849.Peer-Reviewed Original ResearchConceptsInhibition of MIFResponse to infectionNon-canonical signaling pathwaysClinical studiesCancer patientsClinical trialsInflammatory cytokinesDriving tumorigenesisClinical explorationCancer typesCancerDual inhibitionTherapeutic targetIn vivoIn vitroSignaling pathwayMIFAntitumor candidateBinding partnersMacrophage migration inhibitory factor as a therapeutic target in neuro-oncology: A review
Jarmula J, Lee J, Lauko A, Rajappa P, Grabowski M, Dhawan A, Chen P, Bucala R, Vogelbaum M, Lathia J. Macrophage migration inhibitory factor as a therapeutic target in neuro-oncology: A review. Neuro-Oncology Advances 2024, 6: vdae142. PMID: 39233830, PMCID: PMC11372298, DOI: 10.1093/noajnl/vdae142.Peer-Reviewed Original ResearchMacrophage migration inhibitory factorPrimary CNS tumorsCentral nervous systemMigration inhibitory factorCNS tumorsPrimary central nervous systemInhibitory factorTherapeutic targetPre-clinical studiesFunctions of macrophage migration inhibitory factorPreclinical modelsImmune evasionSmall molecule inhibitorsNeuro-oncologyClinical trialsTumor initiationClinical translationMonoclonal antibodiesTumorigenic processNervous systemTherapeutic requirementsCell proliferationTherapeutic developmentTumorEffective target
2013
CD84 is a survival receptor for chronic lymphocytic leukemia cells (P2044)
Marom A, Binsky-Ehrenreich I, Sobotta M, Shvidel L, Berrebi A, Hazan-Halevy I, Kay S, Aloshin A, Sagi I, Goldenberg D, Leng L, Bucala R, Herishanu Y, Haran M, Shachar I. CD84 is a survival receptor for chronic lymphocytic leukemia cells (P2044). The Journal Of Immunology 2013, 190: 132.12-132.12. DOI: 10.4049/jimmunol.190.supp.132.12.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaMacrophage migration inhibitory factorBone marrowAbstract Chronic lymphocytic leukemiaChronic lymphocytic leukemia cellsMigration inhibitory factorCLL cell survivalNovel therapeutic strategiesLymphocytic leukemia cellsCD84 expressionPeripheral bloodLymphoid organsMcl-1 expressionClinical trialsLymphocytic leukemiaCLL cellsTherapeutic strategiesB lymphocytesMalignant cellsInhibitory factorInduces cell deathSurvival receptorCD84Leukemia cellsProtein levels
1995
Advanced glycosylation end products in diabetic renal and vascular disease
Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. American Journal Of Kidney Diseases 1995, 26: 875-888. PMID: 7503061, DOI: 10.1016/0272-6386(95)90051-9.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsGlycosylation end productsPhase II/III clinical trialsNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesRenal functionVascular complicationsDiabetic nephropathyGlomerular sclerosisGlucose-derived Amadori productsEtiologic roleVascular diseaseClinical trialsMatrix protein synthesisTherapeutic modalitiesVascular permeabilityAdvanced glycosylationLipoprotein depositionEnd productsTissue toxicityNitric oxidePharmacologic inhibitorsToxicityProtein synthesis
1994
Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease
Bucala R, Vlassara H, Cerami A. Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease. Drug Development Research 1994, 32: 77-89. DOI: 10.1002/ddr.430320204.Peer-Reviewed Original ResearchAdvanced glycosylationVascular diseasePhase II clinical trialOxidized low-density lipoproteinSpecific therapeutic modalitiesLow-density lipoproteinDirect toxic effectReversible Schiff base adductsClinical trialsAdvanced glycosylation endproductsTherapeutic modalitiesVascular permeabilityDensity lipoproteinLipoprotein depositionVascular wallELISA techniqueHeterogenous groupPathological effectsEndothelial cellsPharmacological inhibitorsPathological conditionsAgeToxic effectsLipoproteinDisease